NEWS & INSIGHTS

BALTIMORE, Md.–(BUSINESS WIRE)– Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer. Dr. Platt brings nearly 20 years of progressive leadership in clinical genomics, guiding teams in developing, validating, and commercializing innovative, high-complexity molecular tests for US and global firms. In this role, Dr. Platt will oversee all of PGDx’s operations related to the company’s product and services delivery capabilities to support the advancement and global impact of the PGDx elioâ„¢ product line.

“The addition of a Chief Operations Officer to the PGDx management team is an invaluable one as we continue to grow our product roadmap and services offerings, driven by relentless commitment to improving cancer care on a global scale,” said Megan Bailey, Chief Executive Officer. “Jamie has a robust resume of achievements in the clinical genomics field, with experience in research, product development, operations and commercial business strategy, and we look forward to her contributions in our work to expand the availability of precision diagnostics for all patients with cancer.”

Dr. Platt most recently served as Chief Operations Officer at Inivata, Inc., where she led the organization’s transition from research-stage through early commercialization, developed and launched two NGS-based liquid biopsy products, and established a significant equity investment and follow-on acquisition by NeoGenomics. She also held roles as Vice President of Genomic Solutions at MPLN and Director of Advanced Sequencing at Quest Diagnostics, introducing a multitude of NGS clinical assays and genomics products. Dr. Platt serves on the boards of Pictor, Ltd., Mobility Health Lab, LLC, and DxTerity Diagnostics. She earned her Ph.D. in Molecular & Cellular Biology from Oregon State University and completed Post-Doctoral studies at University of California at Berkeley.

“I am thrilled to join PGDx and contribute to their mission of increasing the availability of precision diagnostics for patients with cancer through an innovative portfolio of tissue based and liquid biopsy solutions,” said Dr. Platt. “I look forward to building out our infrastructure to enable PGDx to deliver on our responsibility to increase the number of patients receiving personalized care through local testing.”

PGDx currently offers three pan-cancer NGS kitted solutions – elio™ tissue complete, an FDA cleared kit, elio™ plasma complete, a comprehensive liquid biopsy solution, and elio™ plasma resolve, which has received FDA breakthrough device designation – that provide researchers and clinicians with the ability to identify biomarkers and profile tumors through advanced genomic sequencing within their own hospital systems and laboratories.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. PGDx’s elio™ Platform has enabled the development of standardized tissue-based and liquid biopsy next-generation sequencing (NGS) kits for laboratories worldwide, featuring automated bioinformatics that ensures consistent results and quality of testing. By automating the data analysis process, PGDx is enabling the scalability of precision medicine with a fast, reliable, and accurate diagnostics platform. For additional information, visit www.pgdx.com.